Literature DB >> 8692946

Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1.

E Levi1, R Fridman, H Q Miao, Y S Ma, A Yayon, I Vlodavsky.   

Abstract

Recent studies have demonstrated the existence of a soluble fibroblast growth factor (FGF) receptor type 1 (FGFR1) extracellular domain in the circulation and in vascular basement membranes. However, the process of FGFR1 ectodomain release from the plasma membrane is not known. Here we report that the 72-kDa gelatinase A (matrix metalloproteinase type 2, MMP2) can hydrolyze the Val368-Met369 peptide bond of the FGFR1 ectodomain, eight amino acids upstream of the transmembrane domain, thus releasing the entire extracellular domain. Similar results were obtained regardless of whether FGF was first bound to the receptor or not. The action of MMP2 abolished binding of FGF to an immobilized recombinant FGFR1 ectodomain fusion protein and to Chinese hamster ovary cells overexpressing FGFR1 The released recombinant FGFR1 ectodomain was able to bind FGF after MMP2 cleavage, suggesting that the cleaved soluble receptor maintained its FGF binding capacity. The activity of MMP2 could not be reproduced by the 92-kDa gelatinase B (MMP9) and was inhibited by tissue inhibitor of metalloproteinase type 2. These studies demonstrate that FGFR1 may be a specific target for MMP2 on the cell surface, yielding a soluble FGF receptor that may modulate the mitogenic and angiogenic activities of FGF.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8692946      PMCID: PMC38937          DOI: 10.1073/pnas.93.14.7069

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  The kit ligand: a cell surface molecule altered in steel mutant fibroblasts.

Authors:  J G Flanagan; P Leder
Journal:  Cell       Date:  1990-10-05       Impact factor: 41.582

Review 2.  Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.

Authors:  L A Liotta; P S Steeg; W G Stetler-Stevenson
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

Review 3.  Matrix metalloproteinases and their inhibitors in connective tissue remodeling.

Authors:  J F Woessner
Journal:  FASEB J       Date:  1991-05       Impact factor: 5.191

Review 4.  The heparin-binding (fibroblast) growth factor family of proteins.

Authors:  W H Burgess; T Maciag
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

5.  Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix.

Authors:  R Ishai-Michaeli; A Eldor; I Vlodavsky
Journal:  Cell Regul       Date:  1990-10

6.  Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue.

Authors:  C Monteagudo; M J Merino; J San-Juan; L A Liotta; W G Stetler-Stevenson
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

7.  Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2.

Authors:  G I Goldberg; B L Marmer; G A Grant; A Z Eisen; S Wilhelm; C S He
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

8.  Heparan sulfate primed on beta-D-xylosides restores binding of basic fibroblast growth factor.

Authors:  H Q Miao; T A Fritz; J D Esko; J Zimmermann; A Yayon; I Vlodavsky
Journal:  J Cell Biochem       Date:  1995-02       Impact factor: 4.429

9.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.

Authors:  A Yayon; M Klagsbrun; J D Esko; P Leder; D M Ornitz
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

10.  Plasminogen activator and collagenase production by cultured capillary endothelial cells.

Authors:  J L Gross; D Moscatelli; E A Jaffe; D B Rifkin
Journal:  J Cell Biol       Date:  1982-12       Impact factor: 10.539

View more
  104 in total

1.  Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum.

Authors:  C Vaillant; M Didier-Bazès; A Hutter; M F Belin; N Thomasset
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

Review 2.  A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.

Authors:  L Yan; M A Moses
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 3.  Matrix metalloproteinase biology applied to vitreoretinal disorders.

Authors:  C S Sethi; T A Bailey; P J Luthert; N H Chong
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

Review 4.  The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis.

Authors:  C Chang; Z Werb
Journal:  Trends Cell Biol       Date:  2001-11       Impact factor: 20.808

Review 5.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

Review 6.  Proteases at the endometrial-trophoblast interface: their role in implantation.

Authors:  Lois A Salamonsen; Guiying Nie
Journal:  Rev Endocr Metab Disord       Date:  2002-05       Impact factor: 6.514

Review 7.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

8.  Acute venous occlusion enhances matrix metalloprotease activity: Implications on endothelial dysfunction.

Authors:  Tom Alsaigh; Elizabeth S Pocock; John J Bergan; Geert W Schmid-Schönbein
Journal:  Microvasc Res       Date:  2010-10-16       Impact factor: 3.514

9.  Tissue inhibitor of metalloproteinase-2 stimulates mesenchymal growth and regulates epithelial branching during morphogenesis of the rat metanephros.

Authors:  J Barasch; J Yang; J Qiao; P Tempst; H Erdjument-Bromage; W Leung; J A Oliver
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

10.  Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis.

Authors:  Pallavi Garg; Matam Vijay-Kumar; Lixin Wang; Andrew T Gewirtz; Didier Merlin; Shanthi V Sitaraman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-02       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.